| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | PPBL; BENTA; BIMP3; IMD11; CARMA1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human CARD11 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CARD11抗体的3篇文献示例(内容基于公开研究整理，非真实文献)：
---
1. **文献名称**: *CARD11 Autoantibodies in Primary Immunodeficiency Disorders*
**作者**: Smith J, et al.
**摘要**: 研究报道在部分原发性免疫缺陷患者血清中检测到抗CARD11的自身抗体，这些抗体可能通过干扰CARD11-BCL10-MALT1复合体形成，导致T细胞信号传导异常和免疫失调。
2. **文献名称**: *CARD11 Antibody Validation for Flow Cytometry in Lymphoma Studies*
**作者**: Lee H, et al.
**摘要**: 文章验证了一种新型抗CARD11单克隆抗体在流式细胞术中的应用，证明其可特异性识别B细胞淋巴瘤中的CARD11突变体，为肿瘤分型提供工具。
3. **文献名称**: *Role of CARD11 Signaling in Allergic Inflammation Revealed by Neutralizing Antibodies*
**作者**: Garcia R, et al.
**摘要**: 通过使用CARD11中和抗体阻断实验，揭示了CARD11依赖的NF-κB通路在肥大细胞介导的过敏性炎症中的关键作用，提示其作为潜在治疗靶点。
---
*注：以上文献为模拟示例，实际引用请通过PubMed/Google Scholar检索真实研究。*
CARD11 (Caspase Recruitment Domain Family Member 11) is a scaffolding protein critical for antigen receptor-mediated signaling in lymphocytes. It belongs to the membrane-associated guanylate kinase (MAGUK) family and contains a caspase recruitment domain (CARD), a coiled-coil domain, and a PDZ domain. CARD11 plays a pivotal role in activating the NF-κB signaling pathway, which regulates immune cell proliferation, survival, and cytokine production. Upon antigen receptor engagement, CARD11 forms a multiprotein complex with BCL10 and MALT1 (the CBM complex), facilitating downstream NF-κB activation.
Dysregulation of CARD11 is linked to immune disorders and cancers. Germline gain-of-function mutations cause B-cell lymphoproliferative disorders or severe immunodeficiency, while loss-of-function mutations result in primary immunodeficiencies like severe combined immunodeficiency (SCID). Somatic mutations in CARD11 are associated with diffuse large B-cell lymphoma (DLBCL) and other lymphoid malignancies, often leading to constitutive NF-κB activation and uncontrolled cell growth.
CARD11 antibodies are primarily used in research and diagnostics to detect protein expression or mutation status in immune cells. In clinical contexts, they aid in identifying genetic aberrations in immunodeficiencies or lymphomas. Therapeutic targeting of CARD11-related pathways, including inhibitors of the CBM complex or NF-κB, is under investigation for treating autoimmune diseases and cancers. However, direct therapeutic antibodies against CARD11 remain experimental, with current focus on small-molecule inhibitors modulating its signaling cascade.
×
